Insulin Resistance: Measurement and Clinical Interpretation

This article assumes familiarity with the basic biology of insulin resistance, covered in 'Insulin Resistance: Causes and What Actually Changes It.' What follows goes further into a narrower and more practical question: once someone wants to know whether they are insulin resistant, and to what degree, what does the measurement landscape actually look like, and what does a given number mean, and not mean?

Fasting glucose is the cheapest and most widely available test, and it is also the least sensitive for catching insulin resistance early. Because the pancreas compensates for insulin resistance by producing more insulin, fasting glucose can remain in a normal range for years while insulin resistance is already well established underneath that compensation. By the time fasting glucose rises above the normal threshold, the underlying insulin resistance has typically been present for a substantial period already, and some of the pancreas's compensatory capacity (beta-cell function) may already be declining. [1]

Fasting insulin is a more sensitive, though still imperfect, alternative, because it can reveal the compensatory hyperinsulinemia before glucose itself becomes abnormal. There is no single universally agreed threshold, since assay methods differ between labs, but many clinical and research sources treat a fasting insulin level above roughly 8 to 10 microunits per milliliter in someone with a normal fasting glucose as a signal worth further evaluation. Because insulin assays are not standardized across laboratories the way glucose assays are, comparing a fasting insulin result to a generic reference range found online is less reliable than interpreting it alongside a specific lab's own reference interval.

HOMA-IR (the homeostatic model assessment of insulin resistance, calculated from fasting glucose multiplied by fasting insulin, divided by a constant) is the most widely used research metric because it requires only a single fasting blood draw and correlates reasonably well with more invasive gold-standard measurements. A cross-sectional Spanish general-population study (the EPIRCE cohort) found HOMA-IR cutoffs of roughly 1.85 to 2.5 identified insulin resistance using different reference criteria, with values varying by sex and age; this is one dataset among several used to establish commonly cited thresholds, and the specific numeric cutoff a clinician uses can reasonably differ depending on which population and criteria they are referencing. [2] HOMA-IR's main structural limitation is that it more directly reflects hepatic (liver) insulin resistance than resistance in skeletal muscle, and it becomes less reliable as a marker once beta-cell function has declined substantially, since the formula assumes a functioning feedback relationship between insulin secretion and glucose that breaks down in more advanced disease.

An oral glucose tolerance test with paired insulin measurements, drawing blood at fasting, one hour, and two hours after a standardized glucose drink, provides more information than a single fasting value because it shows how the system responds to an actual glucose load rather than just its resting state. An insulin level that spikes above roughly 100 microunits per milliliter and remains elevated at the two-hour mark is generally interpreted as reflecting significant peripheral insulin resistance. This test is more expensive, more time-consuming, and used less routinely than the fasting-only measures. The hyperinsulinemic-euglycemic clamp, which directly measures how much glucose must be infused to maintain normal blood sugar while insulin is held at a fixed elevated level, is considered the reference standard against which all these simpler tests are validated, but it is resource-intensive and used almost exclusively in research settings rather than routine clinical care. [1]

Two markers that do not require any insulin measurement at all are commonly used as indirect surrogates. The triglyceride-to-HDL cholesterol ratio, when triglycerides and HDL are both measured in the same units, has been correlated with insulin resistance across multiple population studies, though the specific cutoff associated with insulin resistance varies somewhat by study population and is not a substitute for direct measurement where that is available. Waist circumference is a second surrogate, tracking with visceral fat mass specifically (the metabolically active fat depot most strongly implicated in driving insulin resistance), and the association between waist circumference and cardiometabolic risk becomes notably steeper above commonly cited population thresholds, though these thresholds also vary by sex, ethnicity, and the specific guideline being referenced.

The clinical relevance of a given HOMA-IR or fasting insulin number depends heavily on what question is being asked. For someone using it to understand whether they may be on a path toward type 2 diabetes, the diagnostic criteria that ultimately matter are the ones defined for prediabetes and diabetes themselves, fasting glucose, A1c, and oral glucose tolerance test results, which are separately validated and standardized in a way that HOMA-IR is not. [3] HOMA-IR and similar research markers are better understood as tools for tracking a trend over time in an individual, or for research classification across groups, than as a stand-alone diagnostic threshold with the same clinical validation as the standard diabetes criteria.

There is also a question, discussed but not yet resolved in the literature, of whether people with more severe baseline insulin resistance and existing gastrointestinal dysfunction (which is common in long-standing metabolic disease, including diabetic gastroparesis) are more vulnerable to the gastric-emptying side effects of GLP-1 receptor agonist drugs. No dedicated randomized trial has directly tested this interaction as its primary question; the concern is grounded in the overlapping mechanism (both conditions independently slow gastric emptying) rather than in a specific trial finding, which places it in the category of Mechanistic Research rather than established clinical evidence. It is a reasonable basis for more cautious monitoring in that population, not a formal contraindication.

Timing and preparation before a blood draw materially affect these results, which is a practical detail often left out of general discussion of these tests. Fasting insulin and glucose both assume a true overnight fast; recent intense exercise, an unusually large previous meal, acute illness, or even significant stress in the hours before the draw can shift both values enough to change a HOMA-IR calculation meaningfully. Some medications, including corticosteroids and certain hormonal therapies, independently raise insulin resistance markers regardless of a person's underlying metabolic state, which is why a single abnormal result taken during an unrelated acute illness or a new medication course is generally interpreted cautiously rather than treated as a stable baseline.

A related interpretive point is that these markers describe insulin resistance as a continuous spectrum, not a binary present-or-absent state. Two people can both have a HOMA-IR above a commonly cited threshold and be in meaningfully different positions: one trending downward after starting an exercise program, the other trending upward with no intervention in place. The single snapshot value is far less informative than the trajectory, which is one reason repeated measurement under consistent conditions, ideally through the same laboratory using the same assay, is generally more useful than a single test result compared against a population-wide cutoff drawn from a different study population entirely.

Limitations worth stating plainly: none of these tests, alone or combined, constitutes a diagnosis of any specific condition, and reference ranges cited in this article are drawn from specific published studies rather than a single universal standard; different laboratories, assay methods, and reference populations can shift the numeric thresholds that apply to an individual result. A single measurement is also a snapshot, sensitive to recent illness, acute stress, recent changes in diet, or a change in medication, and trend over multiple measurements taken under similar conditions is more informative than any one value in isolation. Interpreting these numbers in the context of an individual's full clinical picture, and deciding what if anything to do about a given result, is a task for a clinician, not something this article is positioned to resolve on its own.